Extract
The publication of the first European Respiratory Society guidelines for management of bronchiectasis [1] is a landmark of recent advancement in the field. Whilst the British Thoracic Society guidelines [2] delineated mechanisms of pathogenesis and offered recommendations for management of bronchiectasis, the latest document specifically addressed nine clinically important questions that may better inform clinical decisions. Although it is likely that these recommendations can be extrapolated to patients in Asian countries such as China, we have some further suggestions and/or recommendations for refinement.
Abstract
Macrolides, mucoactive drugs and adherence are crucial for the management of bronchiectasis http://ow.ly/H4oq30fZArC
Acknowledgements
W-J. Guan, Y. Huang and C-L. Chen drafted the manuscript; R-C. Chen and N-S. Zhang critically reviewed the manuscript and approved final submission.
Footnotes
Support statement: This work was supported by National Natural Science Foundation grant number 81400010, Pearl River S&T Nova Program of Guangzhou grant number 201710010097, Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme 2017 (to W-J. Guan), Changjiang Scholars and Innovative Research Team in University grant ITR0961, The National Key Technology R&D Program of the 12th National Five-year Development Plan grant 2012BAI05B01 and National Key Scientific & Technology Support Program “Collaborative innovation of Clinical Research for chronic obstructive pulmonary disease and lung cancer” grant number 2013BAI09B09 (to N-S. Zhong and R-C. Chen). Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
- Received September 28, 2017.
- Accepted September 30, 2017.
- Copyright ©ERS 2018